Clinical Trial Update: Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial evaluating atezolizumab, a PD-L1 inhibitor, in locally advanced cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Locally Advanced Cervical Cancer | Phase 2 | Status: COMPLETED